Add to ORKGMen with metastatic prostate cancer who are treated with androgen deprivation therapies (ADT) usually relapse within 2 to 3 years with disease that is termed castration-resistant prostate cancer (CRPC). To identify the mechanism that drives these advanced tumors, paired-end RNA-sequencing (RNA-seq) was performed on a panel of CRPC bone marrow biopsy specimens. From this genome-wide approach, mutations were found in a series of genes with prostate cancer relevance, including AR
AbstractBackgroundAndrogen-deprivation therapy (ADT) is standard treatment for locally advanced or m...
Castration-resistant prostate cancer (CRPC) is a lethal disease, and improvement with androgen-depri...
Background: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by pr...
Men with metastatic prostate cancer who are treated with androgen deprivation therapies (ADT) usuall...
PurposeProstate cancer is the second leading cause of male cancer deaths. Castration-resistant prost...
The clinical behavior of prostate cancer is highly heterogeneous, with most patients diagnosed with ...
BACKGROUND: Castration-resistant prostate cancer (CRPC) represents a therapeutic challenge for curre...
© 2018 Elsevier Inc. Nearly all prostate cancer deaths are from metastatic castration-resistant pros...
Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a b...
Background Androgen-deprivation therapy (ADT) is standard treatment for locally advanced or metastat...
Prostate cancer is one of the most common cancers diagnosed and the second leading cause of cancer r...
BACKGROUND: Castration‐resistant prostate cancer (CRPC) represents a therapeutic challenge for curre...
Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, ef...
Thesis (Ph.D.)--University of Washington, 2013Novel functionally altered transcripts may be recurren...
[[abstract]]Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progr...
AbstractBackgroundAndrogen-deprivation therapy (ADT) is standard treatment for locally advanced or m...
Castration-resistant prostate cancer (CRPC) is a lethal disease, and improvement with androgen-depri...
Background: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by pr...
Men with metastatic prostate cancer who are treated with androgen deprivation therapies (ADT) usuall...
PurposeProstate cancer is the second leading cause of male cancer deaths. Castration-resistant prost...
The clinical behavior of prostate cancer is highly heterogeneous, with most patients diagnosed with ...
BACKGROUND: Castration-resistant prostate cancer (CRPC) represents a therapeutic challenge for curre...
© 2018 Elsevier Inc. Nearly all prostate cancer deaths are from metastatic castration-resistant pros...
Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a b...
Background Androgen-deprivation therapy (ADT) is standard treatment for locally advanced or metastat...
Prostate cancer is one of the most common cancers diagnosed and the second leading cause of cancer r...
BACKGROUND: Castration‐resistant prostate cancer (CRPC) represents a therapeutic challenge for curre...
Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, ef...
Thesis (Ph.D.)--University of Washington, 2013Novel functionally altered transcripts may be recurren...
[[abstract]]Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progr...
AbstractBackgroundAndrogen-deprivation therapy (ADT) is standard treatment for locally advanced or m...
Castration-resistant prostate cancer (CRPC) is a lethal disease, and improvement with androgen-depri...
Background: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by pr...